Dr. Murahashi began her industry career at Genentech where she managed the LUCENTIS Phase 3 clinical programs in Retinal Vein Occlusion to FDA approval and managed the LUCENTIS high-dose study. After Genentech, Dr. Murahashi was the VP of Clinical Development at Icon Bioscience where she was responsible for the pivotal study of DEXYCU for the treatment of post-operative inflammation. Currently Dr. Murahashi is a consultant to companies and specializes in ophthalmic drug development. Dr. Murahashi received her undergraduate degree from UC Berkeley and her medical degree from Loyola University Chicago. She completed her residency in ophthalmology at the University of Missouri at Columbia and retinal fellowship training at the Retina Institute of Hawaii.